Increased levels of circulating platelet-derived microparticles in psoriasis: Possible implications for the associated cardiovascular risk

Evangelia Papadavid, Konstantina Diamanti, Aris Spathis, Maria Varoudi, Ioanna Andreadou, Kostas Gravanis, Petros Karakitsos, John Lekakis, Dimitrios Rigopoulos, Ignatios Ikonomidis

World Journal of Cardiology · 2016 · 18 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

AIM: To evaluate platelet activation markers in psoriasis patients, compared to controls, and investigate their association with the inflammatory burden of psoriasis. METHODS: ., platelet-monocyte complexes (PMC), platelet-neutrophil complexes (PNC) and platelet-lymphocyte complexes, and concentrations of platelet-derived microparticles (PMPs) using flow cytometry. Both larger-size (0.5-0.9 μm) and smaller-size (< 0.5 μm) PMPs were determined. Serum interleukin (IL)-12 and IL-17 levels were also measured by enzyme-linked immunosorbent assay. The severity of psoriasis was evaluated by the Psoriasis Area Severity Index (PASI). RESULTS: 0.01). CONCLUSION: PMPs, known to be predictive of cardiovascular outcomes, are increased in psoriasis patients, and associated with high inflammatory disease burden. Enhanced platelet activation may be the missing link leading to cardiovascular events in psoriatic patients.

References

33